JERYL L HILLEMAN
CIK 1216628 · Chief Financial Officer · last filed 2026-07-20
JERYL L HILLEMAN is a Chief Financial Officer who has filed 92 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for OMDA, was dated Jul 20, 2026. Across all open-market trades the lifetime net is −$9.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.86M
11
92
-$9.62M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OMDA | Director | 26,655 | $23.67 | $630.9K | $0 | 9 | 2026-07-20 |
| SIBN | Director | 43,772 | $18.61 | $814.6K | -$293.0K | 11 | 2026-06-09 |
| NVCR | Director | 25,471 | $16.39 | $417.5K | -$508.0K | 13 | 2026-06-05 |
| HilleVax, Inc. (HLVX) Delisted | Director | 0 | $2.09 | $0 | $0 | 5 | 2025-09-17 |
| CUTERA INC (CUTR) Delisted | Director | — | $0.10 | — | $0 | 2 | 2024-11-05 |
| NERV | Director | 125 | $4.27 | $534 | $5.2K | 7 | 2023-09-29 |
| Talis Biomedical Corp (TLIS) Delisted | Director | — | $2.84 | — | $0 | 1 | 2021-03-18 |
| Intersect ENT, Inc. (XENT) Delisted | Chief Financial Officer | 43,836 | $28.24 | $1.24M | -$7.51M | 23 | 2019-05-08 |
| XENOPORT INC (XNPT) Delisted | Director | 0 | — | — | $0 | 11 | 2016-07-06 |
| AMYRIS, INC. (AMRS) Delisted | Chief Financial Officer | 594 | $0.05 | $30 | -$1.31M | 4 | 2011-05-23 |
| SYMYX TECHNOLOGIES INC (SMMX) Delisted | Exec. Vice President and CFO | 100,277 | — | — | $0 | 2 | 2007-03-05 |
Recent Filings
92 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-20 | OMDA | Grant (A) | +1,435 | $0 | EDGAR |
| 2026-07-07 | OMDA | Grant (A) | +1,299 | $0 | EDGAR |
| 2026-06-18 | OMDA | Grant (A) | +10,882 | $0 | EDGAR |
| 2026-06-09 | SIBN | Grant (A) | +10,957 | $0 | EDGAR |
| 2026-06-05 | NVCR | Grant (A) | +11,610 | $0 | EDGAR |
| 2026-06-03 | NVCR | Sell (S) | −2,945 | -$46.4K | EDGAR |
| 2026-04-07 | OMDA | Grant (A) | +1,544 | $0 | EDGAR |
| 2026-01-07 | OMDA | Grant (A) | +1,601 | $0 | EDGAR |
| 2025-12-18 | OMDA | Grant (A) | +1,081 | $0 | EDGAR |
| 2025-10-07 | OMDA | Grant (A) | +1,126 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.